RE:RE:RE:RE:RE:RE:RE:REMINDER: BIO-Europe Spring 2014...Hi ronydell.
On point 3, so if you have a drug that works on a particular group of patients, and, this segment of people constitutes a significant group that need help, and, represent a significant financial business, then they are irrelevant and there is no business opportunity???
I'm a mathematicial, a statician and I am a 30 year researcher in other businesses (i.e. not clinical trials). However, I do understand the exploritory value of post hoc analysis and as any scientist I realize that post hoc analysis provides insights and learning in all areas of science, both pure science and applied science. This has been demonstrated time and time again.
I also understand that science is about replication.
As for Don's reputation, I don't know. I hope that I did not invest in a company with the reputation of the "Canadian Wild West of the old Calgary Stock Exchange and the VSE". They are listed on the TSX, the qualificatiions are very high and if they are cheating they run significant risk.
Thanks for sharing the information.
Toinv.